SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kalia Kumud

(Last)

(First)

(Middle)

505 PENOBSCOT DR

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/01/2022

3. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Information Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK	20,530	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
RESTRICTED STOCK UNITS	⁽¹⁾	⁽²⁾	COMMON STOCK	41,747	$0.0	D
STOCK OPTION (RIGHT TO BUY)	⁽³⁾	11/01/2031	COMMON STOCK	22,726	$117.61	D
STOCK OPTION (RIGHT TO BUY)	⁽⁴⁾	04/20/2030	COMMON STOCK	28,670	$74	D

Explanation of Responses:

1. (1)The Restricted Stock Units consist of three grants totaling 41,747 shares outstanding as of May 1, 2022. The first grant was granted on April 20, 2020, of which 10,751 shares are outstanding and vests 25% annually commencing on January 7, 2020. The second grant was granted on September 11, 2020, of which 19,633 shares are outstanding and vests 25% annually commencing on September 9, 2020. The third grant was granted on November 2, 2021, of which 11,363 shares are outstanding, and vests 25% on the first anniversary and quarterly thereafter commencing on September 1, 2021.

2. Not applicable to Restricted Stock Units.

3. The stock option vests and becomes exercisable as to 25% of the shares on September 1, 2022, and then in equal monthly installments through September 1, 2025.

4. The stock option vests and becomes exercisable as to 25% of the shares on January 7, 2021, and then in equal monthly installments through January 7, 2024.

Remarks:

	John Saia	05/11/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.